MDxHealth SA operates as a commercial-stage precision diagnostics company, specializing in urological solutions for markets across the United States, various European nations (including the Netherlands, Belgium, Spain, Poland, and Italy), the broader European Union, and other international territories. The firm's innovative portfolio includes two genomic tests for prostate cancer: SelectMDx, a non-invasive urine-based diagnostic, and ConfirmMDx, an epigenetic test. These offerings provide medical professionals with a reliable method to identify clinically significant prostate cancer, thereby reducing the reliance on potentially complicated invasive procedures.